IRWDIronwood Pharmaceuticals, Inc.
Price
+120%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, undemanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Ironwood Pharmaceuticals, Inc. (IRWD) reported revenue of $113M in Q2 2026 (quarter ended Jun 30, 2026), up 33% from the same quarter a year earlier. That came with net income of $51M (45% of revenue). For the full year FY2025, revenue was $296M (−16% year on year) and net income $24M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 16, 2026Ironwood Pharmaceuticals, Inc. (the “Company”) today announced that, on October 12, 2026, the Board of Directors (the “Board”) appointed Tammi Gaskins, the Company’s Senior Vice President, Chief Commercial Officer, as Chief Executive Officer, effective January 1, 2027 (the “Transition Date”)Director or officer change · Form 8-K
- Aug 6, 2026Raises 2026 Full-Year Financial Guidance Building on.Earnings release · press release
- Jun 18, 2026On June 16, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 39 by RyuScore